A multicenter rendomized open label phase 3 trial to compare the efficacy and safety of Lenvatinib versus Sorafenib in first line treatment of subject with unresectable hepatocellular carcinoma.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Eisai, Inc.
Start Date
November 1, 2013
End Date
October 31, 2019
Administered By
Duke Cancer Institute
Awarded By
Eisai, Inc.
Start Date
November 1, 2013
End Date
October 31, 2019